Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FWB: 496), a
human optimization sciences company that is advancing its clinical pipeline
through its ongoing TBI/PTSD-focused preclinical studies at the University of
Miami’s Miller School of Medicine, today announced that its research partner
and lead investigator, Dr. Michael Hoffer, has obtained a sustainable supply of
psilocybin under a DEA schedule I license, which will be used for ongoing
psilocybin-based therapeutics studies. Under a collaborative research agreement
with the University of Miami’s Miller School of Medicine, Champignon’s wholly
owned subsidiary, Tassili Life Sciences Corp., is conducting preclinical
studies and eventual human clinical trials, with the intention of demonstrating
safety and efficacy of the combination of psilocybin and cannabidiol in
treating mTBI with PTSD or stand-alone PTSD. “We hope to continue to make
significant progress on our preclinical trial studying the effects of an oral
combination of psilocybin and CBD on mTBI associated with PTSD,” Champignon
Brands research partner and lead investigator Dr. Michael Hoffer stated in the
news release. “Since mTBI associated with PTSD is a combination disorder that
affects more than 10 million individuals per year and has no proven medical
treatment, our novel combination of medicines could be a breakthrough in
treating these indications.”
To view the full press release, visit http://ibn.fm/r73iL
About Champignon Brands Inc.
Champignon Brands Inc. is a research-driven company
specializing in the formulation of a suite of medicinal mushrooms health
products, as well as novel ketamine, anaesthetics and adaptogenic delivery
platforms for the nutritional, wellness and alternative medicine industries.
Via its vertically integrated alternative medicine product range, Champignon is
pursuing the development and commercialization of rapid onset treatments
capable of improving health outcomes, such as depression and post-traumatic
stress disorder (“PTSD”), as well as substance and alcohol use disorders. Under
a collaborative research agreement with the University of Miami’s Miller School
of Medicine, the Company is conducting pre-clinical studies and eventual human
clinical trials, with the objective of demonstrating safety and efficacy of the
combination of psilocybin and cannabidiol in treating mTBI with PTSD or
stand-alone PTSD. Champignon continues to be inspired by sustainability, as its
medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For
more information, visit the company’s website at www.Champignonbrands.com.
NOTE TO INVESTORS: The latest news and updates
relating to SHRM are available in the company’s newsroom at http://ibn.fm/SHRM
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment